Cellectis IPO-Jahr
Was ist das IPO-Jahr von Cellectis?
IPO-Jahr von Cellectis ist 2015
Was ist die Definition von IPO-Jahr?
Börsengang ist ein öffentliches Angebot, bei dem Aktien eines Unternehmens normalerweise an institutionelle Anleger verkauft werden, die ihrerseits erstmals an einer Wertpapierbörse an die breite Öffentlichkeit verkauft werden.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO-Jahr von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Cellectis
Was macht Cellectis?
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Unternehmen mit ipo-jahr ähnlich Cellectis
- Global Brands hat IPO-Jahr von 2014
- Antibe Therapeutics hat IPO-Jahr von 2014
- ArcelorMittal 5.50% Mandatorily hat IPO-Jahr von 2014
- The Toronto-Dominion Bank PFD SER 5 hat IPO-Jahr von 2014
- WisdomTree EURO STOXX Banks 3x Daily Leveraged hat IPO-Jahr von 2014
- Horizons Us Lrg Cap Eqty Cvrd C hat IPO-Jahr von 2014
- Cellectis hat IPO-Jahr von 2015
- Larsen & Toubro Infotech hat IPO-Jahr von 2016
- Escape Hunt plc hat IPO-Jahr von 2016
- SiteOne Landscape Supply Inc hat IPO-Jahr von 2016
- Lloyds Steels Industries hat IPO-Jahr von 2016
- Liberty Media hat IPO-Jahr von 2016
- Atlanta Braves Inc hat IPO-Jahr von 2016